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Watch this article's video abstract and others at http://bit.ly/1C2wSLn.
Scan the quick response (QR) code to the left with your mobile device to watch this article's video abstract and others. Don't have a QR code reader? Get one by searching 'QR Scanner' in your mobile device's app store. H epatitis C virus infection (HCV) is one of the leading causes of liver cirrhosis and hepatocellular carcinoma with approximately 170 million people infected with the virus worldwide. 1, 2 Recently, the Centers for Disease Control and Prevention, and later the US Preventive Services Task Force, recommended screening all adults born between 1945 and 1965 for HCV. 3 Fibrosis stage and/or liver stiffness are key predictors of adverse outcomes, and in recent years, liver stiffness assessment using vibration-controlled transient elastography (VCTE) has superseded liver biopsy as a favored noninvasive modality. 4, 5 In fact, draft American Gastroenterological Association guidelines recommend using VCTE to replace liver biopsy in adults with HCV.
Viral eradication (assessed as sustained virologic response [SVR] 12-24 weeks after completion of therapy) has been associated with decline in liver stiffness, caused by a combination of decrease in hepatic inflammation and possible fibrosis regression, but there has been limited assessment of the magnitude of decline. With increasing numbers of patients being cured of HCV, this decline in liver stiffness may be an important consequence of antiviral therapy, translating into favorable long-term clinically relevant outcomes, although definitive evidence in this regard is still lacking.
Hence, we conducted a systematic review of studies with paired liver stiffness measurement using VCTE, before and after antiviral therapy. We estimated (1) magnitude of change in liver stiffness at different time points after antiviral therapy in patients achieving SVR (end of treatment [EOT], 1-6 months after EOT including SVR12, 6-12 months after EOT including SVR24, and >12 months after EOT); (2) magnitude of change in liver stiffness among those who achieve SVR and those who do not achieve SVR, to estimate net decline in liver stiffness after successful viral eradication; and (3) what proportion of patients with baseline liver stiffness >9.5 (corresponding to fibrosis stages, F3 or F4), achieve liver stiffness <9.5 kPa (corresponding to <F3) 6-12 months after viral eradication.
Methods
This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, and the process followed an a priori established protocol, registered on PROSPERO (CRD: CRD42016051034). 6 
Selection Criteria
We included observational studies or randomized controlled trials (RCTs): (1) conducted in adults (>18 years) with HCV who received antiviral therapy (with either direct-acting antiviral agents [DAAs] or interferonbased therapies); (2) underwent liver stiffness measurement using VCTE before starting therapy; (3) at least 1 follow-up VCTE performed after completion of therapy; and (4) provided data on mean/median liver stiffness with measure of variability, stratified by patients who achieved SVR and those who did not achieve SVR (ie, both baseline and follow-up liver stiffness reported separately in patients who achieved SVR and those who did not).
We excluded the following studies: (1) cross-sectional studies with no posttreatment follow-up liver stiffness assessment, (2) studies conducted in untreated patients with HCV or with other etiologies of liver disease (without sufficient subgroup data on patients with HCV), (3) baseline fibrosis assessed only using liver biopsy (without liver stiffness assessment), (4) liver stiffness assessed with noninvasive tools other than VCTE, (5) data were not stratified based on SVR status, or (6) if <80% of the study cohort underwent follow-up VCTE after completion of therapy. In the case of duplicate studies from the same cohort, we included data from the most recent comprehensive report.
Search Strategy
We conducted a systematic search of multiple electronic databases (including Medline, EMBASE, Scopus, Web of Science, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews) from January 1, 2005, to October 31, 2016, with no language restrictions. The search was designed and conducted by an experienced medical librarian with input from the study investigators, using controlled vocabulary supplemented with keywords, for observational studies and RCTs of patients with HCV who underwent antiviral treatment. The details of the search strategy are included in the online supplement. The titles and abstract of studies identified in the search were reviewed by 2 investigators independently (S.S., A.F.) to exclude studies that did not address the research question of interest, based on the aforementioned prespecified inclusion and exclusion criteria; full text of the remaining articles was examined to determine whether it contained relevant and complete information. Additional studies were searched from the bibliographies of the selected articles and review articles on the topic. We also manually searched conference proceedings of major gastroenterology and hepatology conferences (American Association for the Study of the Liver Meeting, European Association for the Study of the Liver International Liver Congress, and Digestive Diseases Week organized in conjunction with the American Gastroenterological Association) from 2013 to 2016 to identify additional studies published only in abstract form. Figure 1 reports the schematic diagram of study selection. Chance-adjusted agreement between reviewers was high, but not formally calculated.
Data Abstraction and Risk of Bias Assessment
Data on the following study-and patient-related characteristics were abstracted onto a standardized form: (1) study characteristics (first author, time period of study/year of publication, country of the population studied); (2) The risk of bias in included studies was assessed using a modified scale derived from the NewcastleOttawa scale, 7 and included the following 6 items: (1) representative of the average adult in the community (1 point for unselected participants in population-based, multicenter studies or RCTs; 0.5 points for unselected participants in single-center hospital-based study; 0 points if nonconsecutive selected group of patients); (2) large cohort size (1 point if size >200 patients, 0.5 points if size between 50 and 200 patients, 0 points if size <50 patients); (3) adequate follow-up length after antiviral therapy (1 point if mean follow-up of cohort >2 years, 0.5 points if 6 months to 2 years, 0 points if <6 months); (4) adequate reporting of conditions in which VCTE was performed both at baseline and follow-up, such as fasting status or transaminase level <2 times the upper limit of normal (1 point if adequately described both preantiviral and postantiviral therapy, 0.5 points if described only at baseline, 0 points if not mentioned); (5) presence of confounders for liver stiffness assessment (which may independently modify Outcomes Assessed
Primary outcome. The primary outcome of interest was change in liver stiffness, 6-12 months after completion of antiviral therapy in those who achieve viral eradication, as compared with pretreatment liver stiffness.
Temporal evolution of liver stiffness after viral eradication. To assess temporal evolution of change in liver stiffness after completion of antiviral therapy, we performed separate analyses based on timing of posttreatment liver stiffness assessment (EOT; within 1-6 months after EOT, including patients with SVR12; 6-12 months after EOT, including patients with SVR24; and >1 year after EOT) in patients who achieved viral eradication.
Subgroup and sensitivity analyses. To understand stability of association and identify factors that may influence magnitude of change in liver stiffness 6-12 months after EOT (or heterogeneity in summary estimate), we performed subgroup analyses based on type of antiviral therapy (DAAs vs interferon-based therapies), baseline cirrhosis either based on author-defined VCTE cutoff (range, 12.5-14.6 kPa) or liver biopsy (>75% of cohort with cirrhosis vs <75% with cirrhosis), coinfection with HIV (>30% with coinfection HIV vs 0%-30% of cohort), geographic location (Western vs Asian), and publication type (full-text vs conference proceedings). Additionally, to understand the impact of baseline factors that may influence change in liver stiffness, we performed metaregression based on mean BMI of cohort, mean pretreatment ALT, and proportion of cirrhosis. We also performed sensitivity analysis, restricting only to high-quality studies.
Secondary outcomes. To estimate net decline in liver stiffness after viral eradication, we compared the change in liver stiffness in those who achieved SVR with those who did not achieve SVR. Finally, we estimated what proportion of patients with pretreatment liver stiffness >9.5 kPa achieved posttreatment liver stiffness <9.5 kPa after SVR.
Statistical Analysis
We used the random-effects model of DerSimonian and Laird to calculate weighted mean difference (WMD) and 95% confidence intervals (CI) between pretreatment and posttreatment liver stiffness in patients who achieved SVR and those who did not achieve SVR. 8 For all analyses, median was consider equivalent to mean, and IQR was converted to standard deviation by dividing by 1.35, and range was transformed to standard deviation by dividing by 4, in accordance with the Cochrane manual. 9 Heterogeneity between study-specific estimates was estimated using the inconsistency index (I 2 ), and cutoffs of <30%, 30%-59%, 60%-75% and >75% suggested low, moderate, substantial, and considerable heterogeneity, respectively. 10 Sources of heterogeneity were investigated using subgroup analyses by stratifying original estimates according to study characteristics asdescribed previously, or using metaregression (for continuous variables); P < .05 was suggestive of the grouping variable being a significant source of heterogeneity. Small study effects were assessed qualitatively using funnel plot asymmetry and quantitatively using the Egger regression test. 11 All analysis was performed using Comprehensive Meta-Analysis version 2 (Biostat, Englewood, NJ).
Results
From a total of 2377 unique studies identified using our search strategy, 23 observational studies and 1 post hoc analysis of an RCT were included in this analysis. Fifteen studies were excluded because of lack of data stratified by SVR status, 22 were excluded because of lack of repeated paired Liver Stiffness Measurement, 15 because they were conducted on untreated patients (or merged data of treated and untreated cohorts), and 4 because of high dropout rate (>20%). Table 2 describes the baseline characteristics of patients in the included studies. The mean age of participants at the time of initial biopsy ranged from 39 years to 67 years; most patients were males. The mean BMI ranged from 22.8 kg/m 2 to 27.8 kg/m 2 , and the mean ALT ranged from 52 IU/L to 110 IU/L. In included studies, 0%-89% of patients had baseline cirrhosis; in 5 studies, >75% of patients had cirrhosis. In 3 studies, >50% patients were coinfected with HIV. Concomitant diabetes, nonalcoholic fatty liver disease, excessive alcohol use, and hepatitis B virus was inconsistently reported, and when reported, was present in <10% of cohort. Patients were treated with interferon-based therapy in 8 studies, and DAAs in 6 studies. Overall, 9 studies were deemed to be at low risk of bias (Supplementary Table 1) . 
Characteristics and Quality of Included Studies

Change in Liver Stiffness in Patients With Viral Eradication
At 6-12 months after end of therapy. On pooled analysis of patients who achieved SVR, the mean liver stiffness declined by 3.2 kPa (95% CI, 2.6-3.9), as compared with pretreatment liver stiffness, 6-12 months after EOT, with substantial heterogeneity (I 2 ¼ 65%) (Figure 2) . 12, 13, 16, 17, [19] [20] [21] [22] [23] [24] [25] 27, 29, 33, 34 The median relative decline in liver stiffness was 28.2% (IQR, 21.8-34.8). In contrast, mean liver stiffness remained fairly unchanged 6-12 months after EOT in patients who did not achieve SVR (WMD, À0.6; 95% CI, À1.7 to 0.5; P ¼ .31; 7 studies).
In 4 studies, with 191 patients who achieved SVR and were classified as having cirrhosis (based on investigatordefined liver stiffness >12.5-14.6 kPa or histology) before therapy, 26.6% (95% CI, 15.9%-40.9%; I 2 ¼ 61%) of patients had decline in liver stiffness to <9.5 kPa. 12, 15, 16, 34 Similarly, from 261 patients who achieved SVR and were classified as having advanced fibrosis or cirrhosis (based on liver stiffness >9.5 kPa), 47.1% (95% CI, 27.1-68.0; I 2 ¼ 89%) of patients had posttreatment liver stiffness <9.5 kPa. 12, 15, 16, 22, 34 Subgroup analysis and metaregression. On subgroup analysis, the magnitude of decline in liver stiffness was higher in patients treated with DAAs (WMD, À4.6 kPa; 95% CI, À3.3 to À5.6) as compared with patients treated with interferon-based therapies (WMD, À2.6; 95% CI, À1.9 to À3.4; P interaction ¼ .03), and in cohorts where most patients had baseline cirrhosis (>75% cirrhosis vs <75% cirrhosis: WMD, À5.1 kPa vs À2.8 kPa; P interaction ¼ .02) ( Table 3) . Of note, although the absolute magnitude of decline was higher in patients with high baseline stiffness, the relative magnitude of decline was comparable. No significant differences were observed based on presence or absence of HIV coinfection or geographic location.
On metaregression, the magnitude of decline in liver stiffness was dependent on baseline ALT (ie, cohorts in which patients had higher mean baseline ALT experienced a more significant decline in liver stiffness after SVR, as compared with patients with lower mean ALT; P < .001) (Supplementary Figure 1A) . Similarly, cohorts with higher proportion of patients with baseline cirrhosis (or higher pretreatment liver stiffness) experienced greater absolute decline in liver stiffness (P ¼ .006) (Supplementary Figure 1B) . No association was observed between baseline BMI and magnitude of decline in liver stiffness (P ¼ .34) (Supplementary Figure 1C) .
Temporal Evolution of Change in Liver Stiffness
In assessing temporal evolution of decline in liver stiffness in patients who achieved SVR, liver stiffness declined by 2.4 kPa (95% CI, 1.7-3.0) at EOT (9 studies), 12, 15, [18] [19] [20] [23] [24] [25] 28, 30 3.1 kPa (95% CI, 1.6-4.6) 1-6 months after EOT (5 studies, including patients with SVR12), 13, 14, 19, 31, 32 and 4.1 kPa (95% CI, 3.3-4.9) >12 months after completion of antiviral therapy (8 studies) (Figure 3) . 12, [15] [16] [17] [24] [25] [26] 28, 35 Overall, this change in stiffness over time was statistically significant (P ¼ .014). In contrast, mean liver stiffness at EOT and >12 months after completion of antiviral therapy in those without SVR was unchanged as compared with pretreatment liver stiffness (EOT: WMD, À0.5 [95% CI, À1.5 to 0.5]; >12 months after EOT: WMD, 0.9 [95% CI, À1.9 to 3.2]). In comparing patients who achieved SVR with no SVR, the overall difference in magnitude of decline in liver stiffness was À3.3 kPa (95% CI, À2.2 to À4.6) at 6-12 months after completion of therapy. This magnitude of difference also increased with increasing time since antiviral therapy (P ¼ .003) (Supplementary Figure 2) .
Sensitivity Analysis and Publication Bias
The primary results were unchanged on sensitivity analysis restricted to high-quality studies (change in liver stiffness in patients with SVR, 6-12 months after EOT: À3.0 [95% CI, À2.1 to À3.9]). There was no evidence of small study effects quantitatively based on funnel plot, or qualitatively based on Egger test (P ¼ .27).
Discussion
Through a systematic review of 24 studies with paired liver stiffness measurement using VCTE, before and after antiviral therapy, we made several key observations. First, liver stiffness decreases significantly, by approximately 3.1 kPa, in 6-12 months after achieving viral eradication; in contrast, liver stiffness remains unchanged in patients who do not achieve SVR. The median Figure 3 . Comparison of change in liver stiffness over time, in patients with HCV who achieve SVR versus patients who do not achieve SVR.
decline in liver stiffness was 28.2%, with an IQR of 21.8%-34.8%. Approximately 47% of patients with baseline liver stiffness in the advanced fibrosis or cirrhosis range (>9.5 kPa), have posttreatment liver stiffness <9.5 kPa. Second, in patients who achieve SVR, the magnitude of decline in liver stiffness is incremental over time after completion of therapy, increasing progressively from À2.4 kPa at EOT to À4.1 kPa at 12 months and beyond. Third, the magnitude of decline in liver stiffness is higher in patients with high baseline liver stiffness, patients treated with DAAs (vs patients treated with interferonbased therapies), and patients with high baseline aminotransferases (a marker of hepatic inflammation before therapy). These findings are directly applicable to patient care and health policy. Because increasing numbers of patients are seeking care and are being cured of HCV, estimation of magnitude of decline in liver stiffness noninvasively after viral eradication may help identify patients likely to be at low risk of liver-related complications (eg, patients without cirrhosis with posttreatment liver stiffness <9.5kPa), although robust evidence of how decline in liver stiffness correlates with improvement in clinically relevant outcomes is very limited.
With increasing reliance on noninvasive modalities for fibrosis assessment in patients with chronic liver diseases, and ease of serial measurement, assessment of change in liver stiffness is perhaps more relevant than change in fibrosis stage. Decline in liver stiffness following viral eradication is probably a combination of resolution of hepatic inflammation, and regression of fibrosis; it is probable that early decline is largely related to resolution of inflammation, whereas continued decline beyond 1 year after EOT may be related to fibrosis regression, as has been observed with paired liver biopsy studies with interferon-based therapy. 36, 37 However, detailed prospective studies are warranted to evaluate short-and long-term implications of rapidity and magnitude of decline in liver stiffness with antiviral therapy. Although progressive increase in liver stiffness has been associated with worsening liver-related complications regardless of fibrosis stage, at this time, it is conjectural that decline in liver stiffness will likely translate into lower risk of liver-related complications.
We observed a greater magnitude of decline in liver stiffness in patients who achieved SVR with DAAs versus interferon-based therapy. This may be related to more rapid clearance of viremia observed with DAAs, with associated rapid decline in hepatic inflammation and fibrogenesis, or potentially higher baseline stiffness in DAA-treated patients resulting in greater magnitude of decline in stiffness. We also observed a greater magnitude of decline in liver stiffness in patients with higher baseline liver stiffness, as compared with those with lower baseline stiffness, and in those with higher baseline ALT. This may be a reflection of higher hepatic inflammatory burden, which responds rapidly to effective antiviral therapy, causing a larger magnitude of change in stiffness, although its clinical significance in terms of more favorable long-term outcomes is still unclear. It is important to note that in cohorts with higher median baseline stiffness, although the absolute decline in liver stiffness with SVR was higher (as compared with cohorts with lower median stiffness), the relative magnitude of decline in stiffness was more homogeneous (28.2% decline [IQR, ). We did not observe any significant difference in change in stiffness based on BMI, on metaregression. There was very limited data on coexisting diabetes, nonalcoholic fatty liver disease, or alcohol consumption, so the potential impact of these ongoing hepatic insults on change in liver stiffness remains to be seen.
The strengths of our systematic review include a (1) comprehensive and systematic literature search with well-defined and restrictive inclusion criteria (limiting to studies in which >80% patients underwent posttreatment VCTE); (2) stratification of analyses by SVR status allowing for comparative assessment, although the number of SVR patients was considerably higher because of the inclusion of several studies reporting only on patients with SVR; (3) recognizing temporal evolution of liver stiffness following SVR and a priori determining primary time point of analysis; (4) rigorous evaluation of study quality, which has been used as the basis for sensitivity analysis; (5) assessment of multiple, clinically relevant end points; and (6) performing several preplanned subgroup and sensitivity analyses and metaregression accounting for key determinants of change in liver stiffness.
There are several limitations in our meta-analysis. First, we did not have access to individual participant data, and hence all analyses were performed at study-level, using mean or median liver stiffness pretherapy and posttherapy to inform magnitude of change in stiffness. Moreover, patients recruited in the studies conducted with DAAs presented higher baseline liver stiffness, which may play a role in the greater magnitude in decline in liver stiffness observed in this subgroup. Second, timing of VCTE post-SVR was also based on mean/median time, as opposed to a fixed time point at which all patients underwent assessment; hence, we used ranges of time of posttreatment VCTE assessment in reporting our analyses. Third, follow-up assessment after SVR was relatively short, hence, long-term evolution of liver stiffness after antiviral therapy and impact of decline in liver stiffness on patient clinical outcomes could not be ascertained. Fourth, studies did not consistently report potential confounders, such as nonalcoholic fatty liver disease, diabetes, and alcohol consumption, which may influence liver stiffness. When variables were available, such as coinfection with HIV or mean BMI, we performed subgroup analysis or metaregression, and observed no significant impact on magnitude of decline in stiffness. Finally, our systematic review focused only on VCTE and no other modalities of liver stiffness assessment, such as shear-wave elastography or acoustic radiation force impulse. 38, 39 In conclusion, liver stiffness measured using VCTE declines significantly after achieving SVR (median, 28.2%), and the magnitude of decline is incremental with time since antiviral therapy. Magnitude of decline is higher in patients treated with DAAs, and in patients with higher baseline stiffness. Approximately 47% of patients with baseline classification of having advanced fibrosis or cirrhosis range liver stiffness, may have decline of posttreatment liver stiffness to <9.5 kPa. With this decline in liver stiffness, it is conceivable that risk of liver-related complications would decrease, particularly in patients without cirrhosis. Future research is warranted on the impact of magnitude and kinetics of decline in liver stiffness on improvement in liver-related outcomes. Quality of included studies was assessed according to the following domains: (1) representative of the average adult in the community (1 point for unselected participants in population-based, multicenter studies or RCTs; 0.5 points for unselected participants in single-center hospital-based study; 0 points if nonconsecutive selected group of patients); (2) large cohort size (1 point if size >200 patients; 0.5 points if size between 50 and 200 patients; 0 points if size <50 patients); (3) adequate follow-up length after antiviral therapy (1 point if mean follow-up of cohort >2 years; 0.5 points if 6 months to 2 years; 0 points if <6 months); (4) adequate reporting of conditions in which TE was performed both at baseline and follow-up, such as fasting status or transaminase level <2 times upper limit of normal (1 point if adequately described both preantiviral and postantiviral therapy; 0.5 points if described only at baseline; 0 points if not mentioned); (5) presence of confounders for liver stiffness assessment (which may independently modify stiffness even after achieving SVR), such as acute hepatitis, HIV, or HBV coinfection, excessive alcohol consumption (1 point if absence of all confounders; 0.5 if presence of 1 confounder in a subset of patients (<30% of cohort); 0 points if >30% of cohort has confounders or data not reported); and (6) other potential sources of risk of bias. Studies with score >4, 3-4, and <3 were suggestive of low, moderate, or high risk of bias.
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